OTCMKTS:ACPGF - Acacia Pharma Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.88
▲ +1.33 (52.16%)
1 month | 3 months | 12 months
Get New Acacia Pharma Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACPGF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACPGF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Acacia Pharma Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.88.
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Acacia Pharma Group.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
1/6/2021Jefferies Financial GroupInitiated CoverageBuy
i
(Data available from 1/25/2016 forward)
Acacia Pharma Group logo
Acacia Pharma Group plc, a hospital pharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, other invasive procedures, or cancer chemotherapy treatments in the United States and internationally. The company's lead product is BAREMSIS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also comprise APD403, an intravenous and oral amisulpride that has completed Phase II clinical trials for the chemotherapy-induced nausea and vomiting treatment; and BYFAVO, an ultra-short-acting and reversible intravenous benzodiazepine sedative/anesthetic, which has completed Phase III clinical trials for the use in invasive medical procedures, such as colonoscopy and bronchoscopy. The company's products are primarily serves anesthesiologists and oncologists. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $3.88
$3.88
$3.88

50 Day Range

MA: N/A

52 Week Range

Now: $3.88
$2.25
$5.00

Volume

1,000 shs

Average Volume

3,069 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Acacia Pharma Group?

The following Wall Street research analysts have issued stock ratings on Acacia Pharma Group in the last year: Jefferies Financial Group Inc..

What is the current price target for Acacia Pharma Group?

0 Wall Street analysts have set twelve-month price targets for Acacia Pharma Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Acacia Pharma Group in the next year.

What is the current consensus analyst rating for Acacia Pharma Group?

Acacia Pharma Group currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACPGF will outperform the market and that investors should add to their positions of Acacia Pharma Group.

How do I contact Acacia Pharma Group's investor relations team?

The company's listed phone number is 44 1223 919760. The official website for Acacia Pharma Group is www.acaciapharma.com.